This trial will test a new treatment for people with inactive chronic hepatitis B who have low levels of hepatitis B surface antigen. The treatment will be evaluated for its ability to fight the virus, its safety, and its ability to provoke an immune response.
1 Primary · 2 Secondary · Reporting Duration: Baseline to Day 169
80 Total Participants · 2 Treatment Groups
Primary Treatment: HepTcell · Has Placebo Group · Phase 2
Age 18 - 65 · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||66.7%|
|Stanford University Department of Medicine||66.7%|
|Toronto Liver Centre||33.3%|